Press Release

Agreement regarding the sales of Mirol Eye Drop 0.5% with Kyorin PharmaceuticalAugust 3, 2000

 Kyorin Pharmaceutical Co., Ltd. and KAKEN PHARMACEUTICAL CO., LTD. signed an agreement regarding a marketing cooperation on Mirol (L-bunolol) Eye Drop 0.5%, an agent for the treatment of glaucoma and ocular hypertension. Kyorin obtained a license of the agent from Allergan, Inc. (U.S.A.) and got a sales and manufacturing approval from Japanese Health Authority as of July 3, 2000. Under this agreement, Kyorin consigned the product for sale in Japan to KAKEN.


 In the process of restructuring the operation, Kyorin has intended to put emphasis on three marketing areas of Respiratory, Otorhinology and Urology. The consignment of Mirol makes it possible for Kyorin to gain more benefit, and to concentrate on the three areas. KAKEN is able to strengthen its product-lines in ophthalmic area by the consignment. Therefore, Kyorin and KAKEN reached an agreement on a marketing cooperation of Mirol. Kyorin supplies the finished-products to KAKEN.


 Mirol indicates good intraocular pressure lowering activity with once daily administration, and its good efficacy and safety for glaucoma and ocular hypertension have been confirmed in the clinical studies. L-bunolol eye drop has been approved among 72 countries in the world since Allergan launched in the U.S. in 1986. Kyorin and KAKEN expect that Mirol will be widely used based on its excellent usefulness in Japan as well as in many other countries.


The features of Mirol are as follows:


Mirol shows excellent clinical efficacy with once daily administration by its continuous intraocular pressure lowering activities due to βreceptor inhibition. Intraocular pressure lowering efficacy rate: 80.5% (165/205 case) Over all efficacy rate: 80.6% (203/252 case)
Due to α1 receptor inhibition, Mirol shows both intraocular pressure lowering activity and ocular blood flow increasing activity.
It is expected for Mirol to protect optic nerve and to arrest the structure of visual field through its ocular blood flow increasing activity.
Low indication of side effects rate: 4.9% (26/530 case: including 46 case with twice a day administration), main symptoms are conjunctival conjestion, smart with administration, and itching.

Back to list